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Abstract
Objective The purpose of this prospective multicenter study
was to assess the safety and technical feasibility of
volumetric Magnetic Resonance-guided High Intensity
Focused Ultrasound (MR-HIFU) ablation for treatment of
patients with symptomatic uterine fibroids.
Methods Thirty-three patients with 36 fibroids were treated
with volumetric MR-HIFU ablation. Treatment capability
and technical feasibility were assessed by comparison of
the Non-Perfused Volumes (NPVs) with MR thermal dose
predicted treatment volumes. Safety was determined by
evaluation of complications or adverse events and unin-
tended lesions. Secondary endpoints were pain and dis-
comfort scores, recovery time and length of hospital stay.
Results The mean NPV calculated as a percentage of
the total fibroid volume was 21.7%. Correlation
between the predicted treatment volumes and NPVs
was found to be very strong, with a correlation
coefficient r of 0.87. All patients tolerated the treatment
well and were treated on an outpatient basis. No serious
adverse events were reported and recovery time to normal
activities was 2.3±1.8 days.
Conclusion This prospective multicenter study proved that
volumetric MR-HIFU is safe and technically feasible for
the treatment of symptomatic uterine fibroids.
Key Points
￿ Magnetic-resonance-guided high intensity focused ultra-
sound allows non-invasive treatment of uterine fibroids.
￿ Volumetric feedback ablation is a novel technology that
allows larger treatment volumes
￿ MR-guided ultrasound ablation of uterine fibroids
appears safe using volumetric feedback
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Introduction
Uterine fibroids are common benign tumors in women,
with a prevalence ranging from 25% to 77% [1, 2]. Fibroids
can cause menorrhagia, pelvic pain, bulk-related symptoms
and infertility, resulting in a reduced quality of life. There
are a variety of therapies available to achieve symptom
relief, including hysterectomy, myomectomy, uterine artery
embolisation and medical therapy [1–5].
Magnetic Resonance-guided High Intensity Focused
Ultrasound (MR-HIFU) is a new, non-invasive treatment
technique for uterine fibroids, where tissue is thermally
ablated by absorption of acoustic energy delivered into the
target tissue using high intensity focused ultrasound [6].
Magnetic Resonance Imaging (MRI) is used for planning
and real-time monitoring of the treatment. A number of
studies have shown the clinical effectiveness of MR-HIFU
for fibroid treatment [7–13].
The traditional approach for MR-HIFU is performed by
iterative sonication of a single focal point, with each
sonication followed by a cooling period (point-by-point
ablation technique) [6, 14]. However, with this approach a
relatively large portion of the delivered energy is lost via
diffusion of heat out of the small targeted region, and long
treatment times are required. Based on recent animal
studies, a novel volumetric ablation technique of temporally
switching the position of a single focal spot along outward-
moving concentric circles, has been proposed to provide a
significant improvement in both treatment efficacy and
ablation homogeneity [15]. Volumetric heating allows
ablation of larger volumes, with diameter of treatment cells
up to 16 mm, and potentially reduces the treatment time.
The purpose of this clinical trial was to assess the safety
and technical feasibility of volumetric MR-HIFU ablation
for treatment of patients with symptomatic uterine fibroids.
Material and methods
This multi-centre prospective study was conducted at four
sites located in France, Korea, Germany, and The Nether-
lands. The trial (NCT00897897) was approved by the
hospitals’ ethical committees and country-specific regula-
tory bodies before trial initiation. All patients gave written
informed consent for inclusion.
Included were pre- or peri-menopausal women with
symptomatic uterine fibroids, 18–59 years of age, uterine
size smaller than 24 weeks of pregnancy, dominant fibroid
size of ≥3c ma n d≤12 cm, transformed Symptom Severity
Score (SSS) of ≥40 points on the Uterine Fibroid Symptom
and Quality of Life Questionnaire (UFS-QoL), and a
normal cervical smear. Exclusion criteria were (desire for
future) pregnancy, general MR imaging contraindications,
other pelvic diseases, and extensive scarring of the lower
abdominal wall because of the increased risk of pain or skin
burns caused by such scars. Screening MR images of the
pelvis were acquired in prone position (1.5 Tesla Achieva,
Philips Healthcare, Best, The Netherlands) using a receive-
only torso XL coil. This included T2-weighted imaging in
three orthogonal planes, and T1-weighted imaging before
and after intravenous administration of a gadolinium-based
contrast agent, Gadopentetate Dimeglumine (Magnevist;
Schering AG, Berlin, Germany, 0.1 mmol per kg body
weight). MR images were used to determine the number of
fibroids, location, size, treatment accessibility, contrast
enhancement and presence of other pelvic diseases.
The day before treatment patients had to complete the
UFS-QoL questionnaire assessing symptoms and quality of
life [16] and depilated the skin of the lower abdomen.
Patients arrived in the clinic in a fasting state. A Foley
catheter was inserted to control bladder volume, and an
intravenous catheter was used to allow administering of
contrast agent and intravenous sedation with fentanyl
citrate. Rectal body temperature was recorded and added
Fig. 1 The Sonalleve MR-HIFU system consists of a 1.5 T clinical
MRI scanner and a 256-element focused ultrasound transducer
integrated in the treatment table top
412 Eur Radiol (2012) 22:411–417to the temperature variation maps inherent to PRF ther-
mometry to obtain absolute temperatures as is necessary for
treatment. Pain and discomfort scores were recorded before
start of treatment. Pain was assessed on a scale from 0 to 10
according to the Visual Analogue Scale, where 0 stands for
‘no pain’ a n d1 0f o r‘worst pain imaginable’ [19].
Discomfort was scored on a scale from 0 to 3: “none” (0),
“mild” (1), “moderate” (2), and “severe” (3).
The patient was positioned on the HIFU tabletop in
prone position, with the fibroid placed above the transducer.
A gel pad and a mixture of degassed water and ultrasound
gel were used to optimise acoustic coupling between the
system and the patient. The patient was given a stop button
to allow her to abort sonication if experiencing pain or
discomfort. Treatment planning was performed based on
3D T2-weighted images of which the system automatically
performed Multiplanar Reconstructions (MPRs) displaying
three orthogonal views (sagittal, transversal and coronal)
simultaneously to facilitate planning. Treatments were
performed with the Sonalleve MR-HIFU system (Philips
Healthcare, Vantaa, Finland), integrated into a 1.5 Tesla
MR imaging system (Fig. 1). Ablation was performed with
a volumetric technique using nominal frequencies of 1.2 or
1.45 MHz [15]. During sonication, the transducer applied
ultrasound energy in a continuous manner in a series of
concentric circular trajectories of increasing size. The
differently sized volumes that the user may choose to be
ablated per sonication, which is also shown as a graphical
object by the system, are called treatment cells. These
treatment cells with nominal diameters of 4, 8, 12 or 16 mm
(and resulting treatment volumes of 0.1, 0.6, 2.3, and
5.4 mL, respectively) were planned within the target
treatment area (Fig. 2). The heating produced by these
volumetric sonications was measured simultaneously with
sonication using Proton Resonance Frequency (PRF) shift-
based MR thermometry [17]. Temperature imaging was
performed in 6 slices (3 target region coronal slices
perpendicular to the beam path; 1 sagittal slice capturing
the heating within the beam path; 1 near-field slice
monitoring for excessive heating of the skin and fat-layer;
1 far-field slice monitoring for excessive heating at the
posterior wall of the fibroid) updated every 3 s using
gradient-echo multi-shot echo planar imaging. The system
provided the option of using the online acquired tempera-
ture information for automatically controlling the sonication
using a thermal feedback method [18], which stops the
sonication when the measured thermal ablation and
temperature profile match with that intended for the chosen
treatment cell.
Immediately post-treatment, T1-weighted MR images
were acquired before and after contrast administration to
visualise the treatment result, i.e. the Non-Perfused Volume
(NPV). Following this, the patients were taken to the
recovery room and monitored before being discharged.
Data on pain, discomfort, and adverse events were
collected. Phone interviews addressing pain and recovery
Fig. 2 Schematic representation
of the volumetric ablation trajec-
tory. The electrically-steered
acoustic focus is moved along
concentric circular sub-
trajectories on a plane perpendic-
ular to the HIFU beam producing
an ellipsoidal thermal volume
(diameter=4, 8, 12 or 16 mm)
Table 1 Patients (n=33) baseline characteristics
Age (years)
a 44.8±5.2
Weight (kg)
a 61.5±10.1
Height (cm)
a 163.8±6.2
Race (%)
b
Caucasian 51.5 (17/33)
Asian 30.3 (10/33)
African American 3.0 (1/33)
South American 6.1 (2/33)
Other 9.1 (3/33)
Inclusions per centre (%)
b
France 48.5 (16/33)
Korea 30.3 (10/33)
Germany 12.1 (4/33)
The Netherlands 9.1 (3/33)
aData are means±standard deviations
bNumbers used to calculate percentages are in parentheses
Eur Radiol (2012) 22:411–417 413were performed 24, 48, and 72 h after treatment, and also at
one and two weeks post-treatment. MR-imaging was
scheduled 1 month after treatment. Quality of life was
assessed 1 month post-treatment using the UFS-QoL [16].
Adverse Events (AEs) were recorded and classified
according to the Society of Interventional Radiology
(SIR) classification [20].
Technical feasibility was assessed by comparison of the
NPVs with MR thermal dose predicted treatment volumes.
Volume measurementsoffibroids and NPVs were performed
based on voxel summation. The volume of interest was
manually segmented with contours on each relevant image
slice. The number of voxels within each contour was
calculated and the sum of voxels multiplied by the voxel
volume to compute the total volume. The NPV was also
calculated as a percentage of the fibroid volume (NPV ratio)
[21]. Safety was determined by evaluation of complications
or AEs and unintended lesions. Pain and discomfort scores,
length of hospital stay, symptom improvement and quality
of life, were assessed as well.
Statistical analysis was performed using the SAS®
statistical package (SAS; SAS Institute, Cary, NC, USA).
Descriptive statistics were used to determine the distribu-
tion of baseline data and outcome measures. Paired t-tests
were used for statistical comparison between baseline and
30 days follow-up for mean pain and quality of life scores;
p-values <0.05 were considered statistically significant.
Results
Thirty-three patients were enrolled in this study, with 38
treatable fibroids. Patient demographics are presented in
Table 1. Three women had more than one fibroid treated.
Two patients were excluded from analyses: one patient
underwent uterine artery embolisation one week after MR-
Fig. 3 Distribution of
fibroid symptoms. The average
number of symptoms per
patient was 3.2 out of 5
Fig. 4 a Thermal dose predicted treatment volume as a function of
non-perfused volume. The diagonal line shows the target performance.
b Bland-Altman plot of thermal dose predicted treatment volume and
non-perfused volume showing absolute difference with mean±1.96
SD acceptance limits
414 Eur Radiol (2012) 22:411–417HIFU treatment, because of unsatisfactory treatment results
due to insufficient heating of the fibroid, and the other
patient underwent surgical fibroid removal in another
hospital for unknown reasons. Figure 3 provides an
overview of the fibroid symptoms in the 31 patients that
were finally included, the most commonly reported symp-
toms being excessive menstrual bleeding and pain.
Technical feasibility was assessed by comparison of the
actual MR-measured NPVs with predicted treatment vol-
umes based on MR thermal dose maps. The mean NPV
calculated as a percentage of the total fibroid volume was
21.7% (range 0–66%), whereas the mean predicted treat-
ment volume was 34.5 mL±30.1. Figure 4a displays the
predicted treatment volume as a function of the NPV for
each fibroid. The correlation coefficient r was 0.87,
representing a very strong correlation. Figure 4b displays
the corresponding Bland-Altman plot of thermal dose
predicted treatment volume and NPV showing the absolute
difference with mean±1.96 SD acceptance limits.
No serious adverse events occurred. A total of 85 AEs
were reported in 31 patients, with a mean of 2.6 AEs per
patient (Table 2). None of the AEs were major according to
the SIR classification [20]. AEs typically resolved within
3 days post-treatment, however two patients reported
ongoing AEs at 30 days follow-up (one patient with sciatic
nerve pain, spontaneously resolved after 139 days, and one
patient with leg pain, resolved after 93 days post-treatment).
Figure 5 shows pain and discomfort scores during follow-
up. Mean baseline reported pain score was 1.8±2.6, with an
increase in pain score to 2.4±2.6, 24 h post-treatment,
however this increase was not significant (p=0.343). At the
end of follow-up, the mean pain score was significantly
reduced to 0.1±0.5 (p=0.002). Mean baseline discomfort
was 0.8±0.8, decreasing to 0.18±0.50 at hospital discharge.
Mean length of hospital stay was 9.3 h±3.3, with a
maximum of 17.0 h. Time needed to return to work and
normal activities ranged from 1–19 days (mean 4.4±4.4)
and 1–7 days (mean 2.3±1.8) respectively.
Discussion
Our results showed that volumetric ablation of uterine
fibroids with the Sonalleve MR-HIFU system is both safe
and technically feasible. No serious adverse events oc-
curred, and concordance between the predicted treatment
volume and the NPV was found in 33 out of 36 treated
fibroids (concordance rate of 92%).
In this study we used the volumetric MR-HIFU
Sonalleve system for treatment of patients with symptom-
atic fibroids. Previous studies used the ExAblate 2000
(InSightec, Haifa, Israel) HIFU system, which uses a
different ablation strategy [6]. The main advantage of the
volumetric ablation technique is that it allows for a
Table 2 Adverse events reported in patients treated with MR-HIFU
Adverse events (AEs) n=31
Pain
Abdominal pain 17 (55%)
Positional related pain 10 (32%)
Sonication related pain 7 (23%)
Sciatic nerve pain 1 (3%)
Gynaecologic
Abdominal discomfort 13 (42%)
Urinary pain or difficulty 7 (23%)
Vaginal bleeding post-treatment 3 (10%)
Haematuria 1 (3%)
Vaginal irritation 1 (3%)
General
Fatigue 6 (19%)
Headache 4 (13%)
Fever>38°Celsius 3 (10%)
Nausea 3 (10%)
Skin irritation 3 (10%)
Other 6 (19%)
Total 85
Data are number of patients, with percentages in parentheses
One patient may have experienced more than one AE
Fig. 5 Mean pain (a, range 0–10) and discomfort (b, range 0–3) scores (including error bars) at consecutive follow-up points
Eur Radiol (2012) 22:411–417 415controlled heating of a larger volume per sonication by
rapid spiral wise movement of the focal spot. Additionally
thermal ablation is controlled utilising feedback control
[15]. This could potentially reduce treatment time for a
given treatment volume in future studies. The aim of this
feasibility study was to assess safety and technical
feasibility. The technical performance rate we found for
the Sonalleve system is at least equal to those reported in
the literature for the ExAblate 2000. In our study, the ratio
between NPVand the predicted treatment volume is 1.4 ±0.6,
while McDannold reported a ratio of 1.9 for the ExAblate
2000 system between the non-perfused area and the predicted
treatment area in the central coronal plane of the treatment
[21]. The match between treated volumes (NPVs) and
predicted treatment volumes in our study was very good
with a 92% concordance rate that may in part be attributed to
the homogeneous ablation with sharp thermal dose borders
produced by the utilised volumetric ablation technique. The
findings of McDannold are also supported by two earlier
feasibility studies from Stewart et al. and Tempany et al. that
showed similar results [6, 14, 21, 23].
Also the safety profile of the Sonalleve system is
similar to what has been reported in the literature for
the ExAblate 2000. Minor adverse events were reported
such as abdominal tenderness, nausea, or first-degree
skin burns. Treatments were performed on an outpatient
basis [6, 14, 22]. Since this feasibility study focused on
safety of a novel MR-HIFU system for treatment of
patients with uterine fibroids, a potential limitation is its
small population included in the study and the relatively
short reported patient follow-up of one month. Longer
follow-up will be needed to report the clinical efficacy of
the treatment as quantified by improvement of symptoms
and an increased quality of life already of patients treated.
These outcomes will be reported in a separate article.
Another limitation of this study was that only a maximum
of 50% ablation of the fibroid volume was allowed.
Recent studies have shown that treatment success is
largely dependent on the ablation volume and the
percentage of ablated fibroid tissue, with increased fibroid
shrinkage, improved symptom relief, and fewer additional
treatments being obtained when larger volumes of the
fibroid are ablated [7, 8, 24, 25]. Fibroid shrinkage is
especially relevant for women suffering from bulk-related
symptoms. MR-HIFU treatment should therefore be
focused on treating as much fibroid tissue as possible.
Reducing safety margins to sensitive structures such as the
bowel and the uterine serosa is inevitable to achieve this,
and has already proven to be safe [26, 27].
In conclusion, this study proved that volumetric MR-
HIFU with the Sonalleve system is safe and technically
feasible for the treatment of symptomatic uterine
fibroids. Future studies will be aimed at treatment of
more patients with larger ablation volumes. Longer
follow-up periods will be required to provide informa-
tion about clinical outcome.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Buttram VC Jr, Reiter RC (1981) Uterine leiomyomata: etiology,
symptomatology, and management. Fertil Steril 36:433–445
2. Stewart EA (2001) Uterine fibroids. Lancet 357:293–298
3. Williams VS, Jones G, Mauskopf J et al (2006) Uterine fibroids: a
review of health-related quality of life assessment. J Womens
Health (Larchmt) 15:818–829
4. Bradley LD (2009) Uterine fibroid embolization: a viable
alternative to hysterectomy. Am J Obstet Gynecol 201:127–
135
5. Goodwin SC, Spies JB, Worthington-Kirsch R et al (2008)
Uterine artery embolization for treatment of leiomyomata: long-
term outcomes from the FIBROID Registry. Obstet Gynecol
111:22–33
6. Tempany CM, Stewart EA, McDannold N et al (2003) MR
imaging-guided focused ultrasound surgery of uterine leiomyo-
mas: a feasibility study. Radiology 226:897–905
7. LeBlang SD, Hoctor K, Steinberg FL (2010) Leiomyoma
shrinkage after MRI-guided focused ultrasound treatment: report
of 80 patients. AJR Am J Roentgenol 194:274–280
8. Fennessy FM, Tempany CM, McDannold NJ et al (2007)
Uterine leiomyomas: MR imaging-guided focused ultrasound
surgery–results of different treatment protocols. Radiology
243:885–893
9. Funaki K, Fukunishi H, Sawada K (2009) Clinical outcomes of
magnetic resonance-guided focused ultrasound surgery for uterine
myomas: 24-month follow-up. Ultrasound Obstet Gynecol
34:584–589
10. Stewart EA, Gostout B, Rabinovici J et al (2007) Sustained relief
of leiomyoma symptoms by using focused ultrasound surgery.
Obstet Gynecol 110:279–287
11. Hesley GK, Felmlee JP, Gebhart JB et al (2006) Noninvasive
treatment of uterine fibroids: early Mayo Clinic experience with
magnetic resonance imaging-guided focused ultrasound. Mayo
Clin Proc 81:936–942
12. Carls GS, Lee DW, Ozminkowski RJ et al (2008) What are the
total costs of surgical treatment for uterine fibroids? J Womens
Health (Larchmt ) 17:1119–1132
13. Zowall H, Cairns JA, Brewer C et al (2008) Cost-effectiveness of
magnetic resonance-guided focused ultrasound surgery for treat-
ment of uterine fibroids. BJOG 115:653–662
14. Stewart EA, Gedroyc WM, Tempany CM et al (2003) Focused
ultrasound treatment of uterine fibroid tumors: safety and
feasibility of a noninvasive thermoablative technique. Am J
Obstet Gynecol 189:48–54
15. Köhler MO, Mougenot C, Quesson B et al (2009) Volumetric
HIFU ablation under 3D guidance of rapid MRI thermometry.
Med Phys 36:3521–3535
16. Chapman A, ter Haar G (2007) Thermal ablation of uterine
fibroids using MR-guided focused ultrasound-a truly non-invasive
treatment modality. Eur Radiol 17:2505–2511
416 Eur Radiol (2012) 22:411–41717. Ishihara Y, Calderon A, Watanabe H et al (1995) A precise and
fast temperature mapping using water proton chemical shift. Magn
Reson Med 34:814–823
18. Enholm JK, Köhler MO, Quesson B et al (2010) Improved
volumetric MR-HIFU ablation by robust binary feedback
control. IEEE Trans Biomed Eng 57:103–113
19. Huskisson EC (1974) Measurement of pain. Lancet 2:1127–
1131
20. Hovsepian DM, Siskin GP, BonnJ et al (2004) Quality improvement
guidelines for uterine artery embolization for symptomatic leiomyo-
mata. Cardiovasc Intervent Radiol 27:307–313
21. McDannold N, Tempany CM, Fennessy FM et al (2006)
Uterine leiomyomas: MR imaging-based thermometry and
thermal dosimetry during focused ultrasound thermal ablation.
Radiology 240:263–272
22. Hindley J, Gedroyc WM, Regan L et al (2004) MRI guidance of
focused ultrasound therapy of uterine fibroids: early results. AJR
Am J Roentgenol 183:1713–1719
23. Hynynen K, Colucci V, Chung A et al (1996) Noninvasive arterial
occlusion using MRI-guided focused ultrasound. Ultrasound Med
Biol 22:1071–1077
24. Lenard ZM, McDannold NJ, Fennessy FM et al (2008)
Uterine leiomyomas: MR imaging-guided focused ultrasound
surgery–imaging predictors of success. Radiology 249:187–
194
25. Kroencke TJ, Scheurig C, Poellinger A et al (2010) Uterine artery
embolization for leiomyomas: percentage of infarction predicts
clinical outcome. Radiology 255:834–841
26. Morita Y, Ito N, Hikida H et al (2008) Non-invasive magnetic
resonance imaging-guided focused ultrasound treatment for
uterine fibroids—early experience. Eur J Obstet Gynecol Reprod
Biol 139:199–203
27. Zhang L, Chen WZ, Liu YJ et al (2010) Feasibility of magnetic
resonance imaging-guided high intensity focused ultrasound
therapy for ablating uterine fibroids in patients with bowel lies
anterior to uterus. Eur J Radiol 73:396–403
Eur Radiol (2012) 22:411–417 417